Link Healthcare, Clinigen Group deal

Clinigen will acquire Link for L22.3 million ($34.2 million) in cash, 3.1 million shares and up to L55.5 million ($84.5 million) in cash milestones. The shares are valued at L23.3 million ($35.8 million) based on Clinigen’s close of 750p on Sept. 21, the day before the deal was announced. Link provides distribution and infrastructure for its own and partnered products, including liver disease drug defibrotide from Jazz Pharmaceuticals plc (NASDAQ:JAZZ, Dublin, Ireland), in Asia, Africa and Australasia. Link also markets generic and partnered drugs for a range of indications in Australia, Africa and Asia. ...